Filing Details

Accession Number:
0001144204-18-042396
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-07 15:18:29
Reporting Period:
2018-08-03
Accepted Time:
2018-08-07 15:18:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175151 Cytosorbents Corp CTSO Surgical & Medical Instruments & Apparatus (3841) 980373793
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1409212 P. Kathleen Bloch C/O Cytosorbents Corporation
7 Deer Park Drive, Suite K
Monmouth Junction NJ 08852
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-08-03 10,000 $2.88 260,004 No 4 M Direct
Common Stock Disposition 2018-08-03 200 $12.85 259,804 No 4 S Direct
Common Stock Disposition 2018-08-03 6,200 $12.75 253,604 No 4 S Direct
Common Stock Disposition 2018-08-03 3,600 $12.15 250,004 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-08-03 10,000 $0.00 10,000 $2.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,000 2023-04-04 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,000 Indirect See Footnote
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").
  2. Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 23,134 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 34,432 shares of common stock owned by the reporting person.
  3. These shares are held by the reporting person's husband in a 401(k) account, and as such, the reporting person may be deemed the beneficial owner of such shares.
  4. These options became exercisable upon the achievement of certain milestones connected to the Company's operations, as determined by the Company's Board of Directors.
  5. The reporting person received an additional $0.599 per share pursuant to the terms of the Trading Plan.